Use of Induced Pluripotent Stem Cells as Screening Tools and Therapeutics Presentations from FDA and Leading Experts

 

Use of Induced Pluripotent Stem Cells

as Screening Tools and Therapeutics

 

Presentations from FDA and Leading Experts

 

A Webinar to be held on September 11, 2014

 

Webinar Information- September 11th from 11 am to 1 pm (PDT)

Fee: None

Link to Webinar Registration (advanced registration required)

 

WEBINAR TOPIC & AGENDA

MODERATOR:

Ellen Feigal, MD, Senior Vice President of Research and Development, CIRM

Speakers:

  • Keith Wonnacott, Ph.D., Chief, Cellular Therapies Branch, Office of Cellular, Tissue and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
  • Steve Finkbeiner, MD, Ph.D., Professor, Departments of Neurology and Physiology, University of California, San Francisco
  • Kyle Kolaja, Ph.D., Vice President, Business Development, Cellular Dynamics
  • Melissa Carpenter, Ph.D., Principal, Carpenter Group Consulting

Topics to be covered:

The focus of this webinar is on the use of Induced Pluriopotent Stem Cells (iPSCs)– used as a tool for disease modeling, target identification, or toxicity assessment, or as a cell therapy intervention.  Speakers will cover preclinical and manufacturing regulatory challenges in moving an iPSC forward as a cell therapy, and challenges along the regulatory pathway in use of iPSCs as tools. 

  • Presentation by FDA - Donor Eligibility and the testing required for iPSCs and hESCs
  • Lessons learned  and regulatory issues for use of iPSC for tools and therapies
  • Questions and Answers

To test your system setup in advance of the September 11 webinar, please go to:

http://www.webex.com/test-meeting.html

The website will simulate joining a Webex meeting and test if you are missing any software, etc.  If you have any technical issues with Webex, please call Webex support at 866.229.3239.

For more information, please see the CIRM website at www.cirm.ca.gov

Resources:

 

 

© 2013 California Institute for Regenerative Medicine